IGM Biosciences (IGMS) Stock Forecast & Price Target

$9.46 +0.06 (+0.64%)

(As of 11/26/2024 ET)

IGM Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 8 Analyst Ratings

Sell
1

Hold
3

Buy
4

Based on 8 Wall Street analysts who have issued ratings for IGM Biosciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 1 has given a sell rating, 3 have given a hold rating, and 4 have given a buy rating for IGMS.

Consensus Price Target

$16.13
70.45% Upside

According to the 8 analysts' twelve-month price targets for IGM Biosciences, the average price target is $16.13. The highest price target for IGMS is $27.00, while the lowest price target for IGMS is $8.00. The average price target represents a forecasted upside of 70.45% from the current price of $9.46.

Get the Latest News and Ratings for IGMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IGM Biosciences and its competitors.

IGMS Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$16.13	$15.00	$16.75	$17.89
Forecasted Upside	70.45% Upside	-10.93% Downside	68.00% Upside	252.14% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

IGMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IGMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IGM Biosciences Stock vs. The Competition

Type	IGM Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	65.05% Upside	25,411.29% Upside	7.11% Upside
News Sentiment Rating	Positive News See Recent IGMS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/11/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy ➝ Buy	$25.00 ➝ $27.00	+117.39%
10/18/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$17.00 ➝ $20.00	+24.77%
10/1/2024	Guggenheim 2 of 5 stars		Lower Target	Buy ➝ Buy	$25.00 ➝ $20.00	+40.65%
10/1/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$25.00 ➝ $22.00	+54.49%
10/1/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$12.00 ➝ $9.00	-45.59%
10/1/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Goonewardene Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00 ➝ $12.00	-27.45%
❗[Investor Alert] Under-the-Radar Tech (Ad) While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO Click here for all the details about today's open round of investing.
9/5/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$12.00 ➝ $11.00	+5.77%
12/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$8.00	+23.08%
11/15/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $8.00	+55.04%
8/7/2023	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
8/7/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$31.00 ➝ $17.00	+87.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:43 PM ET.

IGMS Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for IGM Biosciences is $16.13, with a high forecast of $27.00 and a low forecast of $8.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There is currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IGMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IGMS, but not buy additional shares or sell existing shares.
: According to analysts, IGM Biosciences's stock has a predicted upside of 70.45% based on their 12-month stock forecasts.
: Over the previous 90 days, IGM Biosciences's stock had 2 downgrades by analysts.
: IGM Biosciences has been rated by research analysts at Guggenheim, HC Wainwright, JPMorgan Chase & Co., Royal Bank of Canada, Stifel Nicolaus, Truist Financial, and Wedbush in the past 90 days.
: Analysts like IGM Biosciences less than other "medical" companies. The consensus rating for IGM Biosciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IGMS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

❗[Investor Alert] Under-the-Radar Tech (Ad)

While most investors are caught up in cryptocurrencies, AI stocks, or Jim Cramer's latest "hot pick…" One company that most have never heard of is making waves in the global music market…TuneGO

Click here for all the details about today's open round of investing.

This page (NASDAQ:IGMS) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IGM Biosciences (IGMS) Stock Forecast & Price Target